We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
LGC Clinical Diagnostics

Download Mobile App




Routine Blood Tests Could Speed Up Cancer Diagnosis for People with Abdominal Symptoms

By LabMedica International staff writers
Posted on 31 Jul 2024
Print article
Image: A new study has found that common blood tests could improve early cancer diagnosis (Photo courtesy of Shutterstock)
Image: A new study has found that common blood tests could improve early cancer diagnosis (Photo courtesy of Shutterstock)

Early detection is critical for successful cancer treatment. Yet, many patients with cancer visit their primary care providers with vague symptoms that could result from various benign conditions, complicating the determination of who needs further diagnostic testing or a referral. Most existing guidelines highlight specific "alarm" symptoms for different cancers to guide referrals, but advice on nonspecific symptoms that span multiple cancer types is scarce. Now, a new study has found that incorporating data from routine blood tests could improve cancer risk assessment for patients presenting with abdominal symptoms.

Conducted by researchers at University College London (London, UK), the study utilized data from the UK Clinical Practice Research Datalink, examining over 470,000 patients aged 30 and older who consulted their general practitioner for abdominal pain or bloating. Within one year of these consultations, about 9,000 patients with abdominal pain and 1,000 with bloating were diagnosed with cancer. The study assessed 19 abnormal blood test results from the initial primary care visit to see if these could predict a higher likelihood of a cancer diagnosis. Several blood abnormalities were found to predict cancer risk, regardless of the patient's sex and age. For instance, in patients between 30 and 59 years old presenting with abdominal symptoms, conditions such as anemia, low albumin levels, elevated platelets, abnormal ferritin levels, and increased inflammatory markers were strong predictors of undiagnosed cancer. In patients over 60, symptoms of abdominal pain or bloating alone were considered sufficient for a cancer referral.

Published in PLOS Medicine, the study detailed which cancers were most frequently diagnosed based on age, sex, and specific blood abnormalities. For instance, women aged 50-59 with anemia and abdominal bloating were most commonly diagnosed with bowel and ovarian cancer. This specificity could aid healthcare providers in deciding which diagnostic tests to prioritize. The findings suggest that routine blood tests can offer valuable insights for evaluating patients with nonspecific abdominal symptoms, enhancing cancer risk assessment and pinpointing those who may need further testing or a specialist referral. However, the researchers noted that these results might not directly apply to health systems with different frequencies of blood test usage.

“Our study suggests we can improve cancer detection with blood tests that are already available and that are routinely given to patients with non-specific symptoms whose cause is unclear,” said lead author Dr. Meena Rafiq of the UCL Department of Behavioral Science & Health. “This could be an efficient, affordable way to improve early cancer diagnosis and in some cases increase the likelihood of successful treatment.”

Related Links:
University College London

Gold Member
Veterinary Hematology Analyzer
Exigo H400
Verification Panels for Assay Development & QC
Seroconversion Panels
New
C-Reactive Protein Assay
OneStep C-Reactive Protein (CRP) RapiCard InstaTest
New
TRAb Immunoassay
Chorus TRAb

Print article

Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: The HIV-1 self-testing chip will be capable of selectively detecting HIV in whole blood samples (Photo courtesy of Shutterstock)

Disposable Microchip Technology Could Selectively Detect HIV in Whole Blood Samples

As of the end of 2023, approximately 40 million people globally were living with HIV, and around 630,000 individuals died from AIDS-related illnesses that same year. Despite a substantial decline in deaths... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.